# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### **SCHEDULE 13D**

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

019770106

(CUSIP Number)

Adam Fliss TPG Global, LLC 301 Commerce Street, Suite 3300 Fort Worth, TX 76102 (817) 871-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

### May 14, 2019

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of \$\$240.13d-1(e), 240.13d-1(g), check the following box.  $\square$ 

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 7 Pages)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

<sup>\*</sup>The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No. <u>019770106</u>			SCHEDULE 13D	Page <u>2</u> of <u>7</u> Pages						
	<b>T</b>									
1	NAMES OF REPORTING PERSONS TPG Group Holdings (SBS) Advisors, Inc.									
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) □ (b) □									
3	SEC USE ONLY									
4	SOURCE OF FUNDS (see instructions) OO (See Item 3)									
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) $\Box$									
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware									
NUMBER OF SHARES	7	SOLE VOTING POWER - 0 -								
BENEFICIALLY OWNED BY	8 SHARED VOTING POWER 21,216,306 (See Items 3, 4 and 5)									
EACH REPORTING PERSON	9 SOLE DISPOSITIVE POWER - 0 -									
WITH	10	SHARED DISPO 21,216,306 (See	OSITIVE POWER Items 3, 4 and 5)							
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 21,216,306 (See Items 3, 4 and 5)									
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) $\Box$									
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 17.5% (See Item 5)*									

TYPE OF REPORTING PERSON CO

14

<sup>\*</sup> The calculation is based on 121,539,320 shares of Common Stock (as defined below) outstanding as of May 3, 2019, as reported in the Quarterly Report on Form 10-Q filed by the Issuer (as defined below) with the Securities and Exchange Commission (the "Commission") on May 7, 2019.

CUSIP No. <u>019770106</u>			SCHEDULE 13D	Page <u>3</u> of <u>7</u> Pages						
			'							
1	NAMES OF REPORTING PERSONS David Bonderman									
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) $\Box$ (b) $\Box$									
3	SEC USE ONLY									
4	SOURCE OF FUNDS (see instructions) OO (See Item 3)									
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) $\Box$									
6	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America									
NUMBER OF SHARES	7	SOLE VOTING POWER -0-								
BENEFICIALLY OWNED BY	8	SHARED VOTING POWER 21,216,306 (See Items 3, 4 and 5)								
EACH REPORTING PERSON	9	SOLE DISPOSITIVE POWER -0-								
WITH	10 SHARED DISPOSITIVE POWER 21,216,306 (See Items 3, 4 and 5)									
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 21,216,306 (See Items 3, 4 and 5)									
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) $\Box$									
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 17.5% (See Item 5)*									
14	TYPE OF REPORTING PERSON IN									

<sup>\*</sup> The calculation is based on 121,539,320 shares of Common Stock outstanding as of May 3, 2019, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on May 7, 2019.

CUSIP No. <u>019770106</u>				SCHEDULE 13D	Page <u>4</u> of <u>7</u> Pages					
				•						
1	NAMES OF REPORTING PERSONS James G. Coulter									
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) □ (b) □									
3	SEC USE ONLY									
4	SOURCE OF FUNDS (see instructions) OO (See Item 3)									
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) $\Box$									
6	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America									
NUMBER OF SHARES		7	SOLE VOTING POWER -0-							
BENEFICIALLY OWNED BY		8	SHARED VOTING POWER 21,216,306 (See Items 3, 4 and 5)							
EACH REPORTING PERSON		9	SOLE DISPOSITIVE POWER -0-							
WITH		10	SHARED DISPOSITIVE POWER 21,216,306 (See Items 3, 4 and 5)							
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 21,216,306 (See Items 3, 4 and 5)									
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) □									
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 17.5% (See Item 5)*									
14	TYPE OF REPORTING PERSON IN									

Page 4 of 7 Pages

<sup>\*</sup> The calculation is based on 121,539,320 shares of Common Stock outstanding as of May 3, 2019, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on May 7, 2019.

This Amendment No. 1 (the "<u>Amendment</u>") amends and supplements the Schedule 13D filed by the Reporting Persons on October 25, 2018 (the "<u>Original Schedule 13D</u>" and, as amended and supplemented by this Amendment, the "<u>Schedule 13D</u>"), with respect to the Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

# Item 2. Identity and Background.

This Amendment amends and restates the second paragraph of Item 2 of the Original Schedule 13D in its entirety as set forth below:

"Group Advisors is the sole member of TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is the sole member of each of (i) TPG GenPar VII Advisors, LLC, a Delaware limited liability company and (ii) The Rise Fund GenPar Advisors, LLC, a Delaware limited liability company. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., a Delaware limited partnership, which is the general partner of TPG Carthage Holdings, L.P., a Delaware limited partnership, which it the general partner of The Rise Fund GenPar Advisors, LLC is the general partnership (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 7,072,104 shares of Common Stock."

#### Item 4. Purpose of Transaction.

This Amendment amends and supplements Item 4 of the Original Schedule 13D by inserting the following after the paragraph titled "Investor Rights Agreement":

# "May 2019 Offering

On May 14, 2019, the TPG Funds sold an aggregate of 1,918,755 shares of Common Stock at a price of \$29.38 per share pursuant to Rule 144 under the Securities Act of 1933, as amended."

### Item 5. Interest in Securities of the Issuer.

This Amendment amends and restates the second paragraph of Item 5 of the Original Schedule 13D in its entirety as set forth below:

"(a)-(b) The following sentence is based on 121,539,320 shares of Common Stock outstanding as of May 3, 2019, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on May 7, 2019. Pursuant to Rule 13d-3 under the Act, the Reporting Persons may be deemed to beneficially own 21,216,306 shares of Common Stock, which constitutes approximately 17.5% of the outstanding shares of Common Stock."

Page 5 of 7 Pages

# **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 15, 2019

TPG Group Holdings (SBS) Advisors, Inc.

By: /s/ Michael LaGatta
Name: Michael LaGatta
Title: Vice President

David Bonderman

By: /s/ Bradford Berenson

Name: Bradford Berenson on behalf of David Bonderman (1)

James G. Coulter

By: /s/ Bradford Berenson

Name: Bradford Berenson on behalf of James G. Coulter (2)

- (1) Bradford Berenson is signing on behalf of Mr. Bonderman pursuant to an authorization and designation letter dated March 13, 2018, which was previously filed with the Commission as an exhibit to a Schedule 13G filed by Mr. Bonderman on April 2, 2018 (SEC File No. 005-90172).
- (2) Bradford Berenson is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated March 13, 2018, which was previously filed with the Commission as an exhibit to a Schedule 13G filed by Mr. Coulter on April 2, 2018 (SEC File No. 005-90172).

# INDEX TO EXHIBITS

- 1. Agreement of Joint Filing by TPG Advisors II, Inc., TPG Advisors III, Inc., TPG Advisors V, Inc., TPG Advisors VI, Inc., T3 Advisors, Inc., T3 Advisors II, Inc., TPG Group Holdings (SBS) Advisors, Inc., David Bonderman and James G. Coulter, dated as of February 14, 2011 (incorporated herein by reference to Exhibit 1 to Schedule 13G filed by TPG Group Holdings (SBS) Advisors, Inc., David Bonderman and James G. Coulter on February 14, 2011).
- 2. Form of Lock-Up Agreement by and among certain stockholders and the directors and officers of the Issuer and the Representatives (incorporated by reference to Annex I of Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A filed with the Commission on October 2, 2018).
- 3. Investors' Rights Agreement, dated as of April 6, 2018, by and among the Issuer and certain stockholders listed in Schedule A thereto (incorporated by reference to Exhibit 4.2 to Issuer's Registration Statement on Form S-1 filed with the Commission on September 14, 2018).